TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18 Years to 70 Years~* Performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG) Scale.~* Previously untreated, histological documented, inoperable stage III squamous cell carcinoma of lung, excluding those with pericardial, pleural effusion, and those with contralateral hilar or contralateral supraclavicular lymph nodes.~* Patients must have measurable disease according to RECIST criteria, and all detectable tumor can be encompassed by radiation therapy fields.~* Patient must have adequate blood, liver, lungs and kidney function within the requirements of this study.~* Female patients of child-bearing potential must test negative for pregnancy at the time of enrollment based on a serum pregnancy test. Male and female patients must agree to use a reliable method of birth control during and for 3 months following the last dose of study drug.~* Patients must sign a study-specific informed consent form prior to study entry.~Exclusion Criteria:~* Complete tumor resection, recurrent disease, or those patients eligible for definitive surgery.~* Previous chemotherapy or previous biologic response modifiers for current lung cancer.~* Patient has previously had thoracic radiation therapy.~* Prior or concurrent malignancy except non-melanomatous skin cancer unless disease-free for five years or more.~* Serious concomitant disorders that would compromise the safety of the patient, or compromise the patient's ability to complete the study, at the discretion of the investigator.~* History of significant neurological or mental disorder, including seizures or dementia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Nab-paclitaxel (Type: EXPERIMENTAL): Nab-paclitaxel and carboplatin for Injection; thoracic radiation therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prevalence and Incidence of Central Airway Obstruction in Advanced Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Advanced lung cancer with indication for chemotherapy or chemotherapy + radiation therapy~Exclusion Criteria:~* Age \< 18 year~* Pregnancy~* Refusal to sign informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Lung Cancer (Type: None): All patients with advanced lung cancer candidate for chemotherapy or chemotherapy + radiation therapy will be enrolled and followed-up for 1 year clinically and radiologically (Chest CT) to verify whether or not central airway obstruction is present at the time of diagnosis or occurs in the year following diagnosis (or in the life span from diagnosis and death in patients who die before 1 year of diagnosis). Furthermore, predictor variables possibly associated with central airway obstruction will be studied.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with histologically confirmed, adenocarcinoma of the colon or rectum (mCRC)~* Subjects with KRAS wild-type status of tumour tissue~* Chemotherapy naïve subjects~* Subject who have signed written informed consent (as per institutional protocol)~Exclusion Criteria:~* As per summary of product characteristics of cetuximab

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rheumatoid Arthritis Patients on Adalimumab to Evaluate Its Effect on Synovitis Using Ultrasonography in an Egyptian Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~A patient will be enrolled in this study if he/she fulfills ALL of the following criteria:~* Male or Female patients ≥ 18 years of age with diagnosis of RA~* Patient is eligible to start adalimumab therapy according to the local product label and prescription guidelines~* Patient is naïve to all biologics e.g. anti-cluster of differentiation 4 (anti-CD4) and anti-TNF treatments at the start of the study~* Patient has no history of inflammatory arthritis other than rheumatoid arthritis~* Patient has no history of lymphoma or leukemia or other malignancies~* Has negative result of tuberculosis (TB) screening test or is receiving TB prophylaxis as per local guidelines, Provided written Authorization to the investigator to use and/or disclose personal and/or health data, or Informed Consent if requested by the Local Regulations~Exclusion Criteria:~* Patients that are not diagnosed with rheumatoid arthritis as judged by the American College of Rheumatology criteria~* Patient is currently diagnosed with any condition other than rheumatoid arthritis that may affect radiography progression~* Susceptibility to infections including TB, as judged by the investigator~* Patient is carrier of Hepatitis B virus~* Patient is a pregnant or lactating female at the time of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rheumatoid Arthritis (RA) participants (Type: None): Male or female participants at least 18 years of age with diagnosis of RA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Immune Response to Hepatitis B Virus Booster Vaccination After 20-23 Years

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* healthy adults 20-25 years old~Exclusion Criteria:~* Hepatitis B surface antigen (+)~* Hepatitis B core antibody (+)~* any history of liver disorders including hepatitis~* HIV Ag or Ab(+)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- HBV booster vaccination (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Genetic Predictors of Outcome in HCM Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18+ years of age~* Diagnosed with HCM defined by the presence of left ventricular hypertrophy with minimal wall thickness \>/= 15mm without the presence of hypertension or systemic disease that can account for the degree of hypertrophy.~Exclusion Criteria:~* Hypertension present prior to the diagnosis of HCM~* aortic stenosis with aortic valve area \< 1cm2~* known systemic disease that can cause LVH, such as infiltrative diseases~* able and willing to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient or designated proxy willing and able to provide informed consent prior to enrollment in the study.~* COVID-19 PCR positive on nasopharyngeal swab~* Aged \>/= 18 years old~* Patient hospitalized with newly diagnosed documented severe COVID-19 infection: with respiratory rate \>/= 30 breaths/min OR peripheral capillary oxygen saturation (SpO2) \< 93% on room air for nonintubated pts.~* Fever of 38.5 C or suspected respiratory infection~* IL-6 level \>/= 80 pcg/ml~* Cohort #1 - non intubated Cohort #2 - intubated~* Women of childbearing potential must have a negative serum or urine pregnancy test~* Patients receiving ongoing steroid therapy are eligible~* Patients will be allowed to receive concurrent or sequential treatment with remdesivir~Exclusion Criteria:~* Patients with uncontrolled systemic fungal and bacterial infections~* Patients with latent tuberculosis~* Patients with known hypersensitivity to tocilizumab or any component of the formulation~* Concurrent initiation of steroid therapy is not allowed~* Patients with uncrontroled malignant disease, with a life expectancy of 3 months or less

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intubation/Mechanical Ventilation (Type: EXPERIMENTAL): Progression of respiratory failure in cohort #1 will be defined as a sustained increase in oxygen requirement or need for intubation/mechanical ventilation
- Respiratory Support (Type: EXPERIMENTAL): In cohort #2 progression of respiratory failure will be defined as a need for increasing respiratory support (e.g. FiO2 or PEEP)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Kinect-based Upper Limb Rehabilitation System in Stroke Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age from 20 to 80 years~* Stroke within prior 3 months~* Unilateral upper extremity weakness~Exclusion Criteria:~* Uncontrolled medical conditions~* Who cannot obey the simple command~* Who has the hemispatial neglect, visual impairment, apraxia

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Kinect-based Rehabilitation (Type: EXPERIMENTAL): None
- Self-exercises education (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Combined Patching-Atropine for Residual Amblyopia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 3 to \< 10 years~* Amblyopia associated with strabismus, anisometropia, or both~* Visual acuity in the amblyopic eye between 20/32 and 20/63 inclusive~* Visual acuity in the sound eye 20/32 or better and inter-eye acuity difference \>= 2 logMAR lines~* Current/previous treatment with patching and/or atropine subject to the following stipulations:~  * No simultaneous treatment with patching and atropine in the past 6 months~ * No prior use of atropine in combination with the sound eye spectacle lens reduced by more than 1.50 D~ * Maximum level of any previous treatment:~    * Patching: up to 42 hours per week (averaging 6 hours daily)~   * Atropine: up to once daily~ * Current treatment with 42 hours per week patching or daily atropine~* No improvement in best-corrected amblyopic eye visual acuity between two consecutive visits at least 6 weeks apart using the same testing method and optimal spectacle correction (if needed), with no improvement defined as follows:~  * No lines of improvement~ * For patients tested using E-ETDRS, letter score that is no more than 4 letters improved~* Wearing spectacles with optimal correction (if applicable)~* Investigator ready to wean or stop treatment~Exclusion Criteria:~* Current vision therapy or orthoptics~* Ocular cause for reduced visual acuity~* Prior intraocular or refractive surgery~* Strabismus surgery planned within 10 weeks~* Known allergy to atropine or other cycloplegic drugs~* Known skin reactions to patch or bandage adhesives~* Down Syndrome present

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 9 Years
- Healthy Volunteers: f

Study Arms:
- Intensive (Type: ACTIVE_COMPARATOR): 42 hours per week of patching combined with atropine (1%) once daily in the sound eye, with spectacle correction (if needed)
- Weaning (Type: ACTIVE_COMPARATOR): For patients currently patching, reduce patching to two hours daily for four weeks, then no treatment thereafter except spectacle correction (if needed). For patients currently using atropine, reduce atropine to once weekly for 4 weeks, then no treatment thereafter except spectacle correction (if needed)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot RCT Evaluating a One Stop Vein Clinic

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults over the age of 18 years~* Unilateral lower limb symptoms suggestive of venous disease on the referral letter~Exclusion Criteria:~* Recurrent varicose veins~* Known arterial disease or ABPI\<0.8~* Current deep vein thrombosis~* Patients who withdraw their consent~* Inability to complete the questionnaire or attend follow up appointments~* Currently enrolled in other venous study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- One Stop Vein Clinic (Type: EXPERIMENTAL): Patients randomised to this group will be invited to the One Stop Vein Clinic, offering same day diagnosis and treatment
- Normal Care Pathway (Type: ACTIVE_COMPARATOR): Patients randomised to this group will be invited to the Normal Care Pathway

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Efficacy of a Video Based Intervention to Educate Teen Moms About Fetal Alcohol Syndrome (FAS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant teens aged 12 to 16 years~Exclusion Criteria:

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): The group selected to watch the video.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females 7 years of age or older and able to perform pulmonary function testing~2. Confirmed diagnosis of CF by the 1997 CF Consensus Conference criteria and followed by the VCU or EVMS CF clinic~3. Presence of PA in 2 lower respiratory tract (sputum) cultures in the 24 months before screening~4. Subjects and/or parent guardian must be able to give written informed consent prior to any study related procedure~5. All sexually active female subjects who are of childbearing potential must agree to use an effective method of contraception (i.e.condoms or abstinence).~6. All sexually active female subjects must have a negative pregnancy test at screening (V0).~7. Clinically stable determined by the study physician with no significant new respiratory symptoms.~8. Presence of PA in nasal culture (swab or secretion) or sinus culture obtained in the 12 months before screening or at screening visit~Exclusion Criteria:~1. Use of oral, IV or inhaled antibiotics within 0 days before study other than low dose azithromycin~2. Severe pulmonary disease with FEV1\<30% predicted of baseline SpO2\<0.90~3. ENT surgery within 6 months of screening~4. Allergy or documented adverse reaction to aztreonam~5. Epistaxis or significant (\>30mL) hemoptysis in the past 6 months~6. Frequent (weekly or more frequently) or severe headaches~7. Subject is unlikely to comply with the procedures scheduled in the protocol~8. Subject participates in another clinical trial within 30 days prior to study entry~9. Subjects who have had a lung transplant will be excluded~10. Prisoners will be excluded~11. Non-English Speaking patients will be excluded

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Standard Therapy (Type: ACTIVE_COMPARATOR): Oral Inhalation via PARI Altera Device: Standard Therapy Comparator (Oral Aztreonam 75mg three times a day) AND Nasal Inhalation via PARI PAS Device: Nasal Placebo-Normal Saline twice per day
- Study Therapy (Type: EXPERIMENTAL): Oral Inhalation via PARI Altera Device: Standard Therapy Comparator (Oral Aztreonam 75mg three times a day) AND Nasal Inhalation via PARI PAS Device: Experimental- Nasal Aztreonam 75 mg twice per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Paracetamol, Pregabalin and Dexamethasone on Pain and Opioid Requirements in Patients Having a Tonsillectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for benign tonsillectomy~* Between the ages of 18 and 50 years old~* ASA 1-2 and a surgical technique without the need for local anaesthetics or electrical scissors~Exclusion Criteria:~* Malignancy~* Patients who are unable to cooperate~* Does not speak Danish~* Has allergy for drugs used in the trial~* Has abused drugs and/or medicine~* Epilepsy~* Diabetes treated with medicine~* Treatment with systemic steroids 4 weeks prior to the operation~* Daily use of antacids~* Daily use of analgesics~* Use of antidepressives~* Known kidney disease~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Paracetamol (Type: PLACEBO_COMPARATOR): Oral paracetamol 1 g + placebo + placebo
- Paracetamol + Pregabalin (Type: EXPERIMENTAL): Oral paracetamol 1g + oral pregabalin 300 mg + placebo
- Paracetamol + pregabalin + dexamethasone (Type: EXPERIMENTAL): Oral paracetamol 1g + oral pregabalin 300 mg + IV dexamethasone 8 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The patient must demonstrate his/her continued willingness to participate in the study.~* The patient must be at least 18 years of age, of either gender.~* Patients with chronic hepatitis C (any genotype) who received Peg-IFN alfa-2b + Ribavirin as first treatment for hepatitis C.~* Negative HCV-RNA at the end of treatment (24 or 48 weeks according to the product labeling as appropriate), measured by the assay used at each institution. Only institutions using an assay with a limit of detection of 50 IU/mL or less will be eligible.~Exclusion Criteria:~* Patients who completed treatment with PegInterferon Alfa-2b plus Ribavirin more than 4 weeks before study entry.~* Patients with positive HCV-RNA at the end of treatment (24 or 48 weeks according to the product labeling as appropriate).~* Patients treated for a period shorter than the enrollment period.~* Patients co-infected with human immunodeficiency virus (HIV).~* Patients co-infected with hepatitis B virus (HBV).~* Patients who do not use appropriate effective method of birth control after the end of treatment (according to legal recommendations).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peg-IFN alfa-2b + ribavirin (Type: None): Participants with chronic hepatitis C (CHC) treated with Peg-IFN alfa-2b + ribavirin as first treatment, in common clinical practice, who had negative hepatitis-C virus (HCV)-ribonucleic acid (RNA) by the end of treatment (24 or 48 weeks per product labeling).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues